C4x Discovery Share Discussion Threads

[davemac3] 01/4/2020 12:05

could be because they worked together a few years ago

[timberwolf3] 01/4/2020 11:21

nothing more than an unusual amount of contacts between C4XD and AZN employees on Linkedin.

[bmnsa] 01/4/2020 10:38

Why not aim high!

[timberwolf3] 01/4/2020 09:52

My best guess is that our next partner will be Astrazeneca on NRF-2,

[the stigologist] 01/4/2020 09:25

Worth a read from C4XD website



These are just on Inflammatory diseases. Plenty of other programmes in Oncology and Neurology.

Inflammatory Diseases

Oral NRF-2 activator programme

C4XD has designed and discovered novel potent activators of the NRF-2 pathway, which is important in mediating lung diseases such as Sickle Cell Disease (“SCD”), chronic obstructive pulmonary disease (“COPD”), pulmonary arterial hypertension (“PAH”), and other inflammatory diseases. Multiple C4XD compounds have shown >12 hour NRF-2 activation in the lungs and other target tissues following low dose oral administration in pre-clinical studies. These novel compounds are being optimised for solubility and pharmacokinetic properties for pre-clinical candidate short-list selection.

Pre-clinical data suggests that the anti-oxidant and anti-inflammatory activity provided by NRF-2 activators may ameliorate haemolysis-related complications in SCD such as severe pain episodes, organ damage, heart attacks and stroke and the $41 Billion COPD market represents an area of substantial unmet medical need.

Oral IL-17 Inhibitor programme

Interleukin-17 (“IL-17”) is a high value clinically validated target for inflammation and autoimmune diseases such as psoriasis (estimated to be worth $9 billion per annum). Our programme identified small molecules that can selectively block IL-17 activity whilst keeping the molecular size of the molecule in the traditional “drug-like” range. We have completed optimisation of our lead novel oral compounds which have shown that they can inhibit the release of IL-17 induced cytokines in the blood in vivo when administered orally prior to IL-17 administration. Current marketed drugs that target IL-17 are based on injectable monoclonal antibodies so an oral treatment would increase the number of patients who can access drugs targeting this mechanism and offer the pharmaceutical industry an alternative treatment regime.

Oral α4β7 integrin inhibitor programme

C4XD received an InnovateUK Feasibility Award to fund the early stages of an Oral α4β7 integrin inhibitor programme and we have initiated an evaluation stage drug discovery programme to harness the synergy between its proprietary Conformetrix technology and protein crystallography to expedite the identification of novel, selective α4β7 integrin inhibitors for the treatment of Inflammatory Bowel Disease (“IBD”). IBD is a collection of idiopathic diseases caused by a dysregulated immune response to host intestinal microflora. The most common sub-types are ulcerative colitis and Crohn’s disease. Moderate/severe patients that do not respond to immunosuppressants are progressed on to biological therapies but a significant proportion of patients do not respond to biological therapies and the first effective oral treatment in this disease area is highly sought after.

New Targets from the Treatment of Rheumatoid arthritis

Analysis of a rheumatoid arthritis dataset using C4XD’s proprietary target discovery technology Taxonomy3® identified 66 novel genes that have not previously been associated with this major disease. Of these, nine were prioritised based on corroborative biology in the scientific literature and druggability. These potential targets are from protein families whose function suggests that any resulting drug molecules will have a very different biological impact on disease from that of existing rheumatoid arthritis therapies, enabling considerable therapeutic and commercial differentiation. One of these highly novel drug targets is currently being evaluated as a potential new pipeline programme.

[the stigologist] 31/3/2020 15:38

C4XD twitter account tweeted that LifeArc press release. I suspect they may push NRF2 as a COVID19 play ?

[bmnsa] 31/3/2020 14:43

Just a few,your kidding lol.

[davemac3] 31/3/2020 14:40

That Lifearc announcement does not apply here. A few rampers about today.

[bmnsa] 31/3/2020 12:26

LifeArc launches £10 million research fund to address the challenges of COVID-19
20 Mar 2020

Today, LifeArc, a UK-based medical research charity, has created a £10 million fund to support research to accelerate the development and testing of therapeutics that can be rapidly deployed to treat the symptoms of COVID-19. The charity is seeking applications from academics or companies that have therapeutics that could be repurposed or repositioned for use in COVID-19 patients.

Explaining the urgency of the issue, Melanie Lee, CEO, LifeArc said: “COVID-19 represents a global emergency. The development and manufacture of a vaccine is at least a year away. There is a clear, urgent need now for treatments that can reduce the mortality and morbidity rate.

“We have launched this research call to try to speed up the process of investigating potential treatments and so improve outcomes for patients.”

Development of novel molecules is not realistic in the timeframe, so the focus for applications will be from those looking to repurpose already available medicines licensed in other indications or for therapeutics in the late stages of development.

It is crucial that research funding is made available rapidly to increase the chance of getting an effective treatment available across the world during this pandemic.

Andrew Farquharson, Executive Director, Technology Transfer, LifeArc, said: “We are aware of a number of potential drugs where there is a scientific rationale for testing but no funding to do that.

“With this funding we aim to progress those therapeutics and we are looking for proposals that offer the best chance of quickly making a difference.”

[gussiefinknottle] 31/3/2020 11:31

alloa, you seem to know very little about this company and it's management

[stockhunters] 31/3/2020 11:15

when company rns anything to do with lungs this will multibag ontop of that $294million deal a couple years ago!

i see their partner lifearc fighting covid-19 awsell

ticktock

[alloa2003] 31/3/2020 10:00

The main man at C4XD is obvously great at the science side but rubbish at PR and fund raising negotiations. Get someone in to take on that role and let him do what he does best. Its not rocket science.

[the stigologist] 31/3/2020 09:57

I'll give them a week to put out news they should have already RNSed before i take it up with their brokers and FCA

[the stigologist] 31/3/2020 09:55

I think market has zero faith in Dix

That makes him reticent about putting out news unless it's slam dunk unadulterated great news

And puts extra weight on external validation

Partner NRF2 or progress C4X3256/INDV2000 this stock gets triple whammy boost. Could be spectacular

[the stigologist] 31/3/2020 09:51

Chart is screaming 100p to me

Nuts this went to 200p on original INDV deal

[stockhunters] 31/3/2020 09:37

also bought in today anyone seen vrp shareprice on lung news and that is a £40million market cap!!!

any positive news from C4XD lung program then it is blue skies at this tiny cap

good luck

[toffeeman] 31/3/2020 09:27

I took a small long (to try and recoup some of the losses from 90p!) as I agree with Stig that there is a 20 point gap to be filled.

Stig can be an utter sh1t, but s/he does talk sense on occasion :)

[bmnsa] 31/3/2020 09:24

The phantom red ticker is out of school due to covid19 shut downs.

[bmnsa] 31/3/2020 09:04

Bought in yesterday:))

[davemac3] 31/3/2020 08:52

What covid-19 partners?

[stockhunters] 31/3/2020 08:12

£7million cap with a $290 million deal last year and have covid-19 partners and are working on lung diseases

multibagger when market sees it

[the stigologist] 31/3/2020 00:15

Breakout above 50 day MA on volume

That 20p to 40p is asking to be filled